PRICE: 35 EURO / box 10 Vials
|
Payments accepted:
1. Secure
Bank Transfer Wire
2.
Transferwise
3. Western
Union Online
Shipping outside of
Europe costs 35USD$
(tracking code included).
Minimum order 5boxes
|
For customers from USA and CANADA there are no restrictions from FDA or U.S/CANADA custom to import our Authentic ALFLUTOP Biotehnos
Alflutop
is a natural, injectable formula that is reported to be more effective than
corticosteroid injections, as it not only reduces inflamation, but encourages
repair and regeneration of cartilage and connective tissue. Alflutop has proven
effective in clinical trials in degenerative joint disorders (bursitis,
tendonitis, and arthritis). Comparable in effect, though different in formula
from Adequan, Alflutop is reported to be a miracle drug for joint injuries.
Alflutop is manufactured by BIOTEHNOS S.A. Romania.
Description:
Each 1ml ampule of Alflutop contains 10 mg sea fish bioactive
concentrate (amino acids, low molecular mass peptides, mucopolysaccharides,
trace elements: Na, K, Ca, Mg, Fe, Cu, Zn), and maximum 5mg/100ml phenol as
preservative.
How it works:
Alflutop falls into the group of chondroprotective products
having anti-hyaluronidase, anti-inflammatory and analgesic action.
Alflutop:
inhibits hyaluronidase excess;
restores chondrocytes homeostasis in damaged tissues;
stimulates regenerative processes at cartilage level;
adjusts synovial fluid synthesis;
stimulates superoxide dismutase;
inhibits occurrence of superoxide free radicals.
Dosing:
Intramuscular (IM) injection of 1 amp every day for 3 weeks,
for a 21 day cycle, which can be followed up 2 months later. Intra-articular
(IA) injection has also shown effective in later-stage clinical trials. 1-2
amps into the joint for 21 days.
Alflutop
has an active life of approximately 24-36 hours. The dosing protocols above are
just guidelines, and the bottom line is you should continue treatment as long
as necessary, if need be. There are no indications of toxicity, or any other
negative side effects from Alflutop.
Clinical
Trial Results:
The clinical trials have confirmed the efficacy of Alflutop
in degenerative articular, post-traumatic pathology and abarticular
rheumatism:
extremely few adverse reactions;
lack of major complications;
well tolerated, including the patients sufferring from
gastrointestinal, cardiovascular and metabolic diseases;
and a favourable ratio of costs and clinical efficacy.
The clinical trials showed the therapeutical effect of
Alflutop in the treatment of periarthritis, spondiloarthrosis, spinal disc
injuries, ankylopoietic spondilitis, Reiter syndrome, and rheumatoid
polyarthritis.
References:
1. Svetlova MS, Ignat'ev VK. [Use of alflutop in the
treatment of patients with osteoarthrosis] Klin Med (Mosk). 2004;82(6):52-5.
2. Noskov SM, Fetelego OI, Krasivina IG, Dolgova LN.
[Alflutop in local therapy of shoulder periarthritis] Ter Arkh.
2005;77(8):57-60.
3. Taran AI, Puzanova OG, Lapenko OIe, Sol's'kyi VI,
Samoilova SM. [Experience gained with the use of local administration of
medicinal remedies in rheumatic diseases] Lik Sprava. 2001 Sep-Dec;(5-6):182-5.
1. Svetlova MS, Ignat'ev VK
[Use of alflutop in the treatment of patients with
osteoarthrosis]
Klin Med (Mosk). 2004;82(6):52-5. Russian.
PMID: 15344692 [PubMed - indexed for MEDLINE]
The
efficiency of alflutop was studied in patients with osteoarthrosis (OA) of the
knee or hip joints. The examinees (n = 24) received alflutop only
intramuscularly (in coxarthrosis) or intramuscularly in combination with the
intraarticular injection of the agent (in knee osteoarthrosis). Physical
examinations were made in control periods: before and immediately, 3, 6, and 12
months after treatment. Arthrosonography was used as an objective method for
controlling the efficacy of the drug. The studies have demonstrated that
alflutop substantially relieves pain, improves the function of the diseased
joints in patients with OA. Arthrosonography has shown that the drug exerts an
antiinflammatory effect, retards the progression of a pathological process in
the joint. Alflutop has been found to be more effective in knee OA than in hip
OA, which is determined by that its combined use regimen may be used in knee
OA. The necessity and high efficiency of repeated courses of alflutop therapy
are shown.
PMID: 15344692 [PubMed - indexed for MEDLINE]
2. Noskov SM, Fetelego OI, Krasivina IG, Dolgova LN.
[Alflutop in local therapy of shoulder periarthritis]
Ter Arkh. 2005;77(8):57-60. Russian.
PMID: 16206607 [PubMed - indexed for MEDLINE]
AIM:
To study efficacy of a compound biological preparation alflutop in local
therapy of shoulder periarthritis (SP), to compare its efficacy with that of
periarticular diprospan. MATERIAL AND METHODS: The trial included 54 patients
with SP. Clinical SP forms consisted of subacromial and subdeltoid bursitis
(SSB) (42.6%), tendinitis (57.4%). Acute disease was diagnosed in 35.2%
patients, chronic one--in 64.8%. Alflutop and diprospan were injected
periarticularly. The patients were divided into three groups. Patients of group
1 (n = 15) received alflutop monotherapy (2 ml, 5 injections). Group 2 (n = 24)
received a single injection of diprospan (7 mg). Group 3 (n = 15) patients were
given combined treatment: a single injection (7 mg) of diprospan followed by
alflutop infiltrations (2 mg, 5 injections). The efficacy of the treatment was
judged by some score clinical parameters, dynamometrical findings, SDQ score
set, thermographic and ultrasonic signs of periarticular inflammation. RESULTS:
A course of periarticular alflutop infiltrations in SP demonstrated the same
efficacy as a single dose diprospan. However, in acute SP with bursitis
diprospan produced a significantly better results while alflutop was better in
chronic SP with tendinitis. Diprospan combination with alflutop produced the
highest therapeutic effect irrespective of the disease course and clinical SP
course. CONCLUSION: Local administration of alflutop in SP as monotherapy
alternative to glucocorticosteroids or in combination with diprospan is
effective. A differentiated approach allowing for a clinical form and course of
SP raises therapeutic efficacy noticeably.
PMID: 16206607 [PubMed - indexed for MEDLINE]
3. Taran AI, Puzanova OG, Lapenko OIe, Sol's'kyi VI,
Samoilova SM.
[Experience gained with the use of local administration of
medicinal remedies in rheumatic diseases]
Lik Sprava. 2001 Sep-Dec;(5-6):182-5. Ukrainian.
PMID: 11881370 [PubMed - indexed for MEDLINE]
No comments:
Post a Comment
Note: only a member of this blog may post a comment.